Brief: Cytodyn Announced Continued Positive Data For Its Mtnbc And Mbc Patients
14/02/2020 11:17
Feb 14 (Reuters) - Cytodyn Inc CYDY.PK :
* CYTODYN REPORTS CONTINUED POSITIVE CLINICAL DATA ON ITS
PHASE
1B/2 MTNBC AND EXPANDED ACCESS STUDIES FOR MBC AHEAD OF
BREAKTHROUGH THERAPY DESIGNATION DECISION FROM THE FDA
* CYTODYN INC - ANNOUNCED CONTINUED POSITIVE DATA FOR ITS
MTNBC
AND MBC PATIENTS
Source text for Eikon: ID:nGNX93gvCp
Further company coverage: CYDY.PK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cytodyn
See all newsBrief: Cytodyn Appoints Robert E. Hoffman As Chief Executive Officer
Brief: Cytodyn Closes $17.5 Million Financing To Fund Continued Development Of Leronlimab
Brief: CytoDyn Inc Files For Offering Of Up To 120 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Cytodyn Files For Mixed Shelf Of Up To $100 Million - SEC Filing
Brief: CytoDyn Announces First Patient Dosed in Phase II Oncology Trial in Colorectal Cancer